CANCER TREATMENT REVIEWS
Scope & Guideline
Transforming cancer care with cutting-edge reviews.
Introduction
Aims and Scopes
- Comprehensive Reviews of Therapeutics:
The journal publishes extensive reviews on various therapeutic modalities, including chemotherapy, immunotherapy, targeted therapy, and emerging treatments, ensuring that oncologists are updated on the latest evidence-based practices. - Systematic Reviews and Meta-Analyses:
A significant portion of the journal's content includes systematic reviews and meta-analyses that synthesize data from multiple studies, providing a clearer picture of treatment efficacy and safety across various cancer types. - Focus on Precision Medicine:
CANCER TREATMENT REVIEWS emphasizes precision medicine, exploring how genetic and molecular profiling can guide treatment decisions and improve patient outcomes in oncology. - Interdisciplinary Approach:
The journal promotes an interdisciplinary approach to cancer treatment, integrating insights from various fields such as surgery, radiology, and pharmacology to enhance the understanding and management of cancer. - Emerging and Innovative Therapies:
Regularly features discussions on innovative therapeutic strategies, including novel drug classes, combination therapies, and the role of technology in cancer treatment, thus highlighting cutting-edge research.
Trending and Emerging
- Immunotherapy and Combination Therapies:
Recent publications increasingly focus on immunotherapy, especially its combination with other treatment modalities, highlighting its potential to enhance efficacy in various cancers. - Targeted Therapies and Precision Oncology:
There is a growing emphasis on targeted therapies, particularly those that exploit specific genetic mutations or tumor characteristics, which are becoming central to personalized cancer treatment strategies. - Liquid Biopsy and Biomarker Development:
Emerging themes include the use of liquid biopsies for early cancer detection and monitoring treatment response, along with the development of new biomarkers that guide therapy selection. - Patient-Centered Care Approaches:
The journal is increasingly addressing the importance of patient-centered care, focusing on the incorporation of patient-reported outcomes and shared decision-making in treatment planning. - Management of Treatment-Related Toxicities:
There is a rising trend in discussions about managing side effects and toxicities associated with cancer treatments, reflecting a holistic approach to patient care that prioritizes quality of life.
Declining or Waning
- Traditional Chemotherapy:
There is a noticeable decrease in reviews focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and immunotherapies that offer improved efficacy and reduced toxicity. - Single-Agent Therapies:
The frequency of publications centered on single-agent therapies is declining, as there is a growing emphasis on combination therapies that leverage synergistic effects to enhance treatment outcomes. - Conventional Radiotherapy Techniques:
While radiotherapy remains crucial, discussions surrounding conventional techniques are waning in favor of advanced modalities such as stereotactic body radiotherapy and biologically targeted radiotherapy. - Generalized Treatment Protocols:
The journal has seen a reduction in papers proposing generalized treatment protocols, as the focus shifts towards individualized treatment plans that cater to specific patient profiles and tumor characteristics. - Outdated Biomarkers:
There is less emphasis on older biomarkers that are no longer considered clinically relevant, with more attention being directed towards novel and clinically actionable biomarkers.
Similar Journals
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Pioneering Insights in Cancer Treatment and Research.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.
Cancer Management and Research
Pioneering new paths in cancer management and research.Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.
Molecular Therapy Oncolytics
Pioneering Breakthroughs in Molecular Cancer TreatmentMolecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.
Nature Reviews Clinical Oncology
Pioneering Insights for Tomorrow's TreatmentsNature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.
Oncology in Clinical Practice
Navigating the Landscape of Cancer TreatmentOncology in Clinical Practice is a vital resource in the field of oncology, published by VIA MEDICA in Poland. This peer-reviewed journal, with ISSN 2450-1654 and E-ISSN 2450-6478, aims to bridge the gap between clinical practice and cancer research, providing a platform for the dissemination of original research, reviews, and case studies. Since its inception in 2019, the journal has featured significant contributions to the understanding of cancer treatment and patient care, although it currently holds a Q4 ranking in Oncology with a Scopus rank of #313/404 and a 22nd percentile in the Medicine _ Oncology category. Though it is not an open-access journal, its content is invaluable for oncologists, researchers, and students, offering critical insights and advancements in clinical approaches to cancer management. With a commitment to enhancing patient outcomes through clinical evidence, Oncology in Clinical Practice serves as an essential reference for those dedicated to the fight against cancer.
Chinese Clinical Oncology
Bridging experimental and clinical oncology for a healthier future.Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.
Cancer Research and Treatment
Empowering discoveries, enhancing treatments.Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.
Journal of Kidney Cancer and VHL
Shaping the dialogue on kidney cancer advancements.The Journal of Kidney Cancer and VHL stands as a leading platform for disseminating cutting-edge research in the field of renal oncology, particularly focused on kidney cancer and Von Hippel-Lindau (VHL) disease. Published by CODON PUBLICATIONS since its inception, this Open Access journal, with ready accessibility since 2014, aims to foster knowledge exchange and collaboration among researchers, clinicians, and healthcare professionals dedicated to improving outcomes for patients with kidney cancer. With an ISSN of 2203-5826, this journal serves as a vital resource in the academic community, encouraging submissions that span various topics, including epidemiology, treatment modalities, and innovative therapeutic strategies. By providing unrestricted access to its content, the Journal of Kidney Cancer and VHL promotes inclusive participation in the global dialogue surrounding these critical health challenges, ensuring that the latest findings reach all corners of the scientific community.
Clinical Genitourinary Cancer
Pioneering discoveries for improved patient outcomes.Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Elevating Cancer Research to New HeightsAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.